Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 4.56% in Q3 FY26, the lowest of these four quarters.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 36.9% | 18.9% | 7.0% | 5.1% |
| ROIC | 16.3% | 9.3% | 5.1% | 4.6% |
Debt
Net debt is 5.30× a year’s EBITDA. Debt is 1.11× equity, against 1.22× in Q2 FY26.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.9× | 1.0× | 1.2× | 1.1× |
| Net debt / EBITDA | 4.9× | −24.3× | 38.2× | 5.3× |
Cash cycle, in days
Customers pay in 69 days, inventory is held 118 days and suppliers are paid in 96. Cash is tied up for 91 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 116 | 123 | 117 | 91 |
| Days to pay suppliers | 98 | 82 | 78 | 96 |
| Days to be paid | 66 | 68 | 69 | 69 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 20.9%; revenue has grown 5.07%; book value has fallen 13.5%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 1.2× | 1.3× | 1.2× |
| Revenue | 1.0× | 1.0× | 1.0× | 1.1× |
| Book value | 1.0× | 0.9× | 0.8× | 0.9× |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 5.07% | 6.97% | 18.94% | 36.86% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 4 | 4 | 4 | |
| 1.87% | 2.57% | 7.33% | 14.37% | ||
ROIC |
4.56% | 5.08% | 9.33% | 16.28% | |
Return on Tangible Assets |
6.81% | 9.15% | 26.67% | 45.07% | |
Average Days of Receivables |
69.04 | 68.89 | 67.76 | 66.11 | |
Free Cash Flow per Share |
5.97 | 6.50 | 5.71 | 4.94 | |
Free Cash Flow |
14,746.00 | 16,063.00 | 14,115.00 | 12,360.00 | |
Capital Expenditures |
(3,957.00) | (3,904.00) | (3,775.00) | (4,112.00) | |
| Other line items | |||||
Cash ROIC |
14.14% | 16.03% | 14.36% | 10.84% | |
Accounts Receivable Turnover |
5.42 | 5.45 | 5.72 | 5.90 | |
Accounts Payable Turnover |
4.15 | 4.66 | 4.49 | 3.86 | |
Inventory Turnover |
3.02 | 2.81 | 2.71 | 2.57 | |
Average Days of Payables |
96.48 | 77.62 | 82.18 | 98.12 | |
Days of Inventory on Hand |
118.21 | 125.89 | 137.83 | 148.34 | |
Tax Rate |
(0.49) | (0.47) | (0.23) | (0.13) | |
Research and Development Expense of Revenue |
45.65% | 45.75% | 37.65% | 24.29% | |
Selling, General and Administrative Expense of Revenue |
16.90% | 16.73% | 16.54% | 16.51% | |
Share Based Compensation of Revenue |
1.57% | 1.34% | 1.23% | 1.26% | |
Operating CF/Net income |
7.62 | 6.29 | 2.00 | 0.90 | |
Depreciation/Fixed assets |
0.28 | 0.26 | 0.25 | 0.23 | |
Capex/Depreciation |
(0.54) | (0.58) | (0.60) | (0.70) | |
Revenue per Share |
27.30 | 26.95 | 26.61 | 25.98 | |
Operating CF per Share |
7.58 | 8.08 | 7.24 | 6.58 | |
Capex per Share |
(1.60) | (1.58) | (1.53) | (1.64) | |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.06 |